The view that HDC/IL-2 is efficacious in NPM1+ AML is bolstered by pronounced treatment efficacy in myelomonocytic/monocytic forms of AML (FAB classes M4/M5) where NPM1 mutations accumulate69 (Table 1). This evidence concerns the gene IL2 and acute myeloid leukemia.